Stockscreener 앱 받기
9.89
5.99%
-0.63
시간 외 거래:
9.90
0.010
+0.10%
전일 마감가:
$10.52
열려 있는:
$10.45
하루 거래량:
2.70M
Relative Volume:
1.44
시가총액:
$843.75M
수익:
$42.95M
순이익/손실:
$-130.01M
주가수익비율:
-6.0757
EPS:
-1.6278
순현금흐름:
$-19.66M
1주 성능:
+0.20%
1개월 성능:
-29.71%
6개월 성능:
-43.65%
1년 성능:
-4.90%
1일 변동 폭
$9.8525
$10.54
1주일 범위
$9.68
$10.75
52주 변동 폭
$8.9431
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
9.89 | 843.75M | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6%What's Next? - MarketBeat
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial - Kalkine Media
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com
Monte Rosa Therapeutics (Nasdaq:GLUE)Stock Analysis - Simply Wall Street
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE - MarketBeat
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Share Price, GLUE Stock News, GLUE Share Price & Updates - Kalkine
Can Monte Rosa Therapeutics (NASDAQ:GLUE) Rewrite Its Story? - Kalkine Media
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone - Yahoo Finance
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com India
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - moomoo.com
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
GLUE stock gains on investor conference plans and Monte Rosa outlook - ad-hoc-news.de
Six new hires get stock awards from Monte Rosa - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive - Sahm
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance
Monte (GLUE) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Current Update; Session Move - vinanet.vn
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monte Rosa Therapeutics Inc 주식 (GLUE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Warmuth Markus | President & CEO |
Jul 16 '26 |
Sale |
23.18 |
9,500 |
220,219 |
585,038 |
| MARKUS WARMUTH | Officer |
Jul 16 '26 |
Proposed Sale |
23.18 |
9,500 |
220,219 |
0 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Officer |
Jul 15 '26 |
Proposed Sale |
23.38 |
4,351 |
101,730 |
0 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
| Townson Sharon | Chief Scientific Officer |
Jul 06 '26 |
Sale |
23.31 |
6,000 |
139,849 |
67,845 |
| Townson Sharon | Chief Scientific Officer |
Jul 06 '26 |
Option Exercise |
6.14 |
6,000 |
36,840 |
73,845 |
| Janku Filip | Chief Medical Officer |
Jun 30 '26 |
Sale |
24.50 |
5,407 |
132,472 |
60,612 |
| FILIP JANKU | Officer |
Jun 30 '26 |
Proposed Sale |
23.90 |
5,407 |
129,227 |
0 |
| Janku Filip | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
13.41 |
5,407 |
72,508 |
66,019 |
7.08%
1.32%
자본화:
|
볼륨(24시간):